In Focus: GioTag

The GioTag study investigated TKI sequencing in real-world patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who develop T790M. The final data confirmed those of previous analyses and demonstrated that sequential afatinib followed by osimertinib is a feasible and effective therapeutic strategy.

In our latest In Focus feature, learn more about the GioTag study design and concept and hear the authors explain the results in their own words.

Read the full paper

FEATURES

GioTag

Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis

Take a look at the abstract for the final GioTag article, which summarises the key conclusions that can be taken from the data and briefly describes the methods used.

 

GioTag infographic

Check out the infographic to visualize the GioTag’s study concept, and key design aspects and results.